Nanotechnology in adjuvants and vaccine development: what should we know?

[1]  R. Adamo,et al.  Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines. , 2021, Molecular pharmaceutics.

[2]  A. Gholami,et al.  Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review , 2021, International Journal of Biological Macromolecules.

[3]  Carlo Pifferi,et al.  Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action , 2021, Nature Reviews Chemistry.

[4]  A. Pollard,et al.  A guide to vaccinology: from basic principles to new developments , 2020, Nature reviews. Immunology.

[5]  Suh-Chin Wu,et al.  Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination , 2020, Journal for ImmunoTherapy of Cancer.

[6]  Xun Sun,et al.  Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[7]  O. Leo,et al.  Activation of the endoplasmic reticulum stress sensor IRE1α by the vaccine adjuvant AS03 contributes to its immunostimulatory properties , 2018, npj Vaccines.

[8]  R. A. van den Berg,et al.  Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity , 2017 .

[9]  Robert Langer,et al.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. , 2017, Nano letters.

[10]  N. Garçon,et al.  From discovery to licensure, the Adjuvant System story , 2016, Human vaccines & immunotherapeutics.

[11]  M. Amiji,et al.  The impact of size on particulate vaccine adjuvants. , 2014, Nanomedicine.

[12]  XinRan Li,et al.  Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[13]  E. Oviedo-Orta,et al.  Progress in understanding adjuvant immunotoxicity mechanisms. , 2011, Toxicology letters.

[14]  Mario Cortese,et al.  Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. , 2011, Vaccine.

[15]  H. Pehamberger,et al.  A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study , 2010, Breast Cancer Research and Treatment.